ConductScience.org, home

Paper23116010

Multivalent ligand: design principle for targeted therapeutic delivery approach.

Chittasupho C. Ther Deliv, 2012. Cited by 61 papers, by iCite.

Cite this record

ConductScience Library. Multivalent ligand: design principle for targeted therapeutic delivery approach. Papers, record 23116010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23116010

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multivalent ligand: design principle for targeted therapeutic delivery approach.
PubMed
Journal
Ther Deliv
PubMed
Year
2012
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
61
iCite
Relative citation ratio, by iCite
1.73
iCite
Revised in PubMed
2019-11-12
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chittasupho CChuda

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug Delivery SystemsMajor topic
Drug DesignMajor topic
Animals
Binding Sites
Humans
Ligands
Thermodynamics

Source PubMed

Download CSV of topics

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.

PMIDTitleJournalYearIn PapersSource
42711843Dual-Target Nectin-4/FAP Heterobivalent Probe 68Ga/177Lu-FZ-NF-1 for Triple-Negative Breast Cancer: Preclinical Theranostic Evaluation and First-in-Human Translation.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42711843PubMed
41550162Targeted drug conjugates in cancer therapy: Challenges and opportunities.Pharm Sci Adv2024https://conductscience.org/library/papers/41550162PubMed
39365862P2X7 receptors exhibit at least three modes of allosteric antagonism.Sci Adv2024https://conductscience.org/library/papers/39365862PubMed
39092437Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component.RSC Chem Biol2024https://conductscience.org/library/papers/39092437PubMed
38661191Multivalent DNAzyme agents for cleaving folded RNA.Nucleic Acids Res2024https://conductscience.org/library/papers/38661191PubMed
38176714Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.J Nucl Med2024https://conductscience.org/library/papers/38176714PubMed
37760428Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies.Cancers (Basel)2023https://conductscience.org/library/papers/37760428PubMed
37181631Identification of multidentate tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors that simultaneously access the DNA, protein and catalytic-binding sites by oxime diversification.RSC Chem Biol2023https://conductscience.org/library/papers/37181631PubMed
37142301Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αvβ3 in Various Cancer Types.J Nucl Med2023https://conductscience.org/library/papers/37142301PubMed
36558148Nerve Targeting via Myelin Protein Zero and the Impact of Dimerization on Binding Affinity.Molecules2022https://conductscience.org/library/papers/36558148PubMed
36128509Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1.RSC Chem Biol2022https://conductscience.org/library/papers/36128509PubMed
36034180Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD.Biochem Eng J2022https://conductscience.org/library/papers/36034180PubMed
35942040Multivalent ACE2 engineering-A promising pathway for advanced coronavirus nanomedicine development.Nano Today2022https://conductscience.org/library/papers/35942040PubMed
35589404A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.J Nucl Med2022https://conductscience.org/library/papers/35589404PubMed
35439047Discovery of unusual dimeric piperazyl cyclopeptides encoded by a Lentzea flaviverrucosa DSM 44664 biosynthetic supercluster.Proc Natl Acad Sci U S A2022https://conductscience.org/library/papers/35439047PubMed
35013982Critical parameters for design and development of multivalent nanoconstructs: recent trends.Drug Deliv Transl Res2022https://conductscience.org/library/papers/35013982PubMed
34982497Significance of Receptor Mobility in Multivalent Binding on Lipid Membranes.Angew Chem Int Ed Engl2022https://conductscience.org/library/papers/34982497PubMed
34847142Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site.PLoS One2021https://conductscience.org/library/papers/34847142PubMed
34163656Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites.Chem Sci2021https://conductscience.org/library/papers/34163656PubMed
33073549Ligand Density Controls C-Type Lectin-Like Molecule-1 Receptor-Specific Uptake of Polymer Nanoparticles.Adv Biosyst2020https://conductscience.org/library/papers/33073549PubMed

See all 27 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23116010

GET https://conductscience.org/api/papers/v1/23116010/cited_by?page=2